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Abstract
Background: Carbonic anhydrase IX (CA IX) is a tumor-associated, highly active, transmembrane carbonic
anhydrase isoform regulated by hypoxia and implicated in pH control and adhesion-migration-invasion. CA IX
ectodomain (ECD) is shed from the tumor cell surface to serum/plasma of patients, where it can signify cancer
prognosis. We previously showed that the CA IX ECD release is mediated by disintegrin and metalloproteinase
ADAM17. Here we investigated the CA IX ECD shedding in tumor cells undergoing apoptosis in response to
cytotoxic drugs, including cycloheximide and doxorubicin.
Methods: Presence of cell surface CA IX was correlated to the extent of apoptosis by flow cytometry in cell lines
with natural or ectopic CA IX expression. CA IX ECD level was assessed by ELISA using CA IX-specific monoclonal
antibodies. Effect of recombinant CA IX ECD on the activation of molecular pathways was evaluated using the cell-
based dual-luciferase reporter assay.
Results: We found a significantly lower occurrence of apoptosis in the CA IX-positive cell subpopulation than in the
CA IX-negative one. We also demonstrated that the cell-surface CA IX level dropped during the death progress due
to an increased ECD shedding, which required a functional ADAM17. Inhibitors of metalloproteinases reduced CA IX
ECD shedding, but not apoptosis. The CA IX ECD release induced by cytotoxic drugs was connected to elevated
expression of CA IX in the surviving fraction of cells. Moreover, an externally added recombinant CA IX ECD
activated a pathway driven by the Nanog transcription factor implicated in epithelial-mesenchymal transition and
stemness.
Conclusions: These findings imply that the increased level of the circulating CA IX ECD might be useful as an
indicator of an effective antitumor chemotherapy. Conversely, elevated CA IX ECD might generate unwanted effects
through autocrine/paracrine signaling potentially contributing to resistance and tumor progression.
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Background
Carbonic anhydrase IX (CA IX) belongs to a carbonic
anhydrase family of enzymes that use a zinc-activated
hydroxide mechanism to catalyze the reversible conver-
sion of carbon dioxide to carbonic acid in the net reac-
tion CO2 + H2O ↔ HCO3
− +H+ [1, 2]. Via this catalytic
activity, carbonic anhydrases either supply bicarbonate
for biosynthetic reactions and ion transport across mem-
branes or consume produced/transported bicarbonate.
Their proper performance is essential for various physio-
logical processes in virtually all organisms. Human CAs
exist in 15 isoforms that differ by subcellular localization
and kinetic properties [3].
In contrast to other CA isoforms that are mostly
present in differentiated cells, expression of CA IX is
limited to only few normal tissues, mainly the epithelia
of gastrointestinal tract [4]. On the other hand, CA IX is
closely associated with a broad range of tumors that ei-
ther suffer from hypoxia or contain inactive pVHL [5].
This expression pattern is principally determined by a
strong HIF-1-mediated transcriptional activation of the
CA9 gene, which contains an HRE element localized on
the negative DNA strand immediately upstream of the
transcription start site [5].
Despite the dramatic induction by hypoxia, intratu-
moral distribution of the CA IX protein only partially
overlaps with the distribution of low p02 measured by
microelectrodes and with the distribution of other
markers of hypoxia, such as pimonidazole, HIF-1α,
GLUT-1 and VEGF. This can be explained by the high
post-translational stability of the CA IX protein, which
reflects both actual and expired hypoxia [6], and by its
regulation by other microenvironmental factors, such as
acidosis [7] and/or by shedding of the extracellular do-
main of CA IX [8, 9].
CA IX is primarily expressed as a transmembrane pro-
tein localized on the surface of tumor cells, where it
contributes to regulation of pH through facilitation of
bicarbonate transport to the cytoplasm for intracellular
alkalinization and to production of protons in the peri-
cellular space for microenvironmental acidosis [10, 11].
CA IX also supports cell adhesion and spreading, and
promotes epithelial-mesenchymal transition through
stimulation of cell migration and invasion [12, 13].
These attributes of CA IX determine its role in the pro-
tection of tumor cells from hypoxia and acidosis.
About 10 % of the cell-associated CA IX molecules
undergo constitutive ectodomain (ECD) shedding, which
is sensitive to the metalloproteinase inhibitor batimastat.
This basal ECD release can be several-fold induced by
the treatment with PMA and pervanadate and the in-
duction depends on the presence of ADAM17, a disinte-
grin and metalloproteinase also called the TNF-α
converting enzyme [9]. Thus, the cleavage of the CA IX
ECD appears to be a regulated process that responds to
signal-transduction stimuli and may contribute to the
adaptive changes in the protein composition of tumor
cells and of their microenvironment.
A growing number of experimental and clinical studies
have demonstrated correlations of CA IX expressed in
tumor or stromal cells to aggressive phenotype, resist-
ance to chemo-/radiotherapy and poor cancer prognosis
in a spectrum of tumor types [14]. On the other hand,
potential clinical value of the CA IX ectodomain is not
so clear. While certain studies support its prognostic/
predictive value, others fail to find any significant rela-
tionship between the CA IX ECD levels and clinical pa-
rameters [15–23]. These controversial data may be
caused by the use of different detection assays [24], but
also by poor understanding of the clinically relevant sig-
nals contributing to induction of the CA IX ECD release
and its biological consequences.
Here we studied the effect of a cytotoxic drug treat-
ment on the shedding of the CA IX ECD and found that
the level of the CA IX ECD is increased in response to
induction of apoptosis by inhibition of proteosynthesis,
as well as by treatment with the chemotherapeutic drug
doxorubicin. Our data suggest that the production of
CA IX ECD is a consequence of cell death and imply
that the ECD released from tumor cells can either indi-
cate cytotoxic effect of chemotherapy or mediate signal-
ing that promotes cancer development.
Methods
Cell culture
CGL3 hybrid cell line was generated by fusion of cervical
carcinoma HeLa cells with normal human fibroblasts
[25]. HeLa cells with endogenous, hypoxia-inducible ex-
pression of CA IX, and MDCK-CA9 cells transfected
with the full-length CA9 cDNA and exhibiting constitu-
tive CA IX expression were described earlier [10]. CHO-
wt and shedding-defective CHO-M2 cells (with inactive
ADAM17) were generously provided by prof. Joaquin
Arribas (Vall d’Hebron Institute of Oncology, Barcelona)
[26]. The cells were grown in DMEM supplemented
with 10 % FCS under standard conditions. Experiments
in hypoxia (2 % O2) were done in an anaerobic worksta-
tion (Ruskinn Technologies) with 5 % CO2, 10 % H2 and
83 % N2 at 37 °C.
Inhibitors and drugs
Metalloproteinase inhibitor BB-94 (batimastat; British
Biotechnology Ltd), Z-VAD-FMK (caspase inhibitor IV,
Calbiochem), cycloheximide (CHX), doxorubicin (DOX),
actinomycin D (ActD), dexamethasone (DX), phorbol
12-myristate 13-actetate (PMA, all from Sigma-Aldrich)
were dissolved in dimethyl sulphoxide and stored in ali-
quots at −20 °C. Prior to use, the inhibitors were diluted
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in culture medium to working concentrations (10 μM
BB-94, 10 μM PMA, 20–100 μg/ml CHX, 1 μM Z-VAD-
FMK, 10 μM DX, 2 μg/ml ActD, and 1 μg/ml DOX).
The cells were plated at a density of 30–50 000 cells/
cm2, and incubated for 24 h at 37 °C. The treatment pe-
riods varied for individual agents, for CHX, ActD, DX
and PMA it was 3–6 h, for DOX it was 24 h at 37 °C in
normoxic or hypoxic conditions. Parallel control dishes
were maintained in the same conditions for the same
time periods.
For inhibition of shedding, CGL3 cells were plated and
allowed to attach for 24 h at 37 °C, and then incubated
for additional 24 h in normoxia or hypoxia. After 1 h in-
cubation in fresh serum-free DMEM medium, the cells
were treated with BB-94 inhibitor for 1.5 h, and with
CHX for additional 3 h at 37 °C in normoxia or hypoxia.
Assay with the caspase inhibitor Z-VAD-FMK was
performed using HeLa cells plated, allowed to attach
overnight and incubated for 24 h in hypoxia to induce
the expression of CA IX. Then the medium was replaced
with fresh serum-free medium containing 1 μM caspase
inhibitor Z-VAD-FMK. Six hours later, doxorubicin was
added at a final concentration of 1 μg/ml and the cells
were incubated for additional 20 h. The cells were har-
vested for qPCR and FACS analyses and media were col-
lected for ECD assessment by ELISA.
Antibodies
The primary antibodies were as follows: M75 and IV/18
anti-human CA IX mouse monoclonal antibodies recog-
nizing the N-terminal proteoglycan-like domain and V/
10 mouse monoclonal antibody specific for the extracel-
lular catalytic domain were described earlier [27].
Secondary anti-mouse antibodies conjugated with horse-
raddish peroxidase were purchased from Sevapharma,
donkey anti-mouse IgG Alexa Fluor 488 or 594 were
from Invitrogen, and horse anti-mouse FITC-conjugated
antibody from Vector Laboratories.
Quantitative real-time PCR (qPCR)
Total RNA was extracted using the Instapure reagent
(Eurogentec). RNA was transcribed with a High-
Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems) using random heptameric primers. Quantitative
real-time PCR was performed on a StepOne Real-Time
PCR System (Applied Biosystems) using POWER SYBR
Green PCR Master Mix (Applied Biosystems) and the
following primers: CA9 sense: 5′-TATCTGCACTCCTG
CCCTCTG-3′ and CA9 antisense: 5′-CACAGGGTGTC
AGAGAGGGTG-3′; Nanog sense: 5′-GCAAATGTCTT
CTGCTGAGATGC-3′ and Nanog antisense: 5′-AGCT
GGGTGGAAGAGAACACAG-3′; β-actin sense: 5′-
TCCTCCCTGGAGAAGAGCTA-3′ and β-actin anti-
sense: 5′-ACATCTGCTGGAAGGTGGAC-3′.
Cloning and purification of the recombinant CA IX ECD
DNA fragment encoding the extracellular part of the CA
IX protein (aa 38–406) was cloned in the pSecTag2A
plasmid and expressed as a recombinant fusion protein
HisTag-CA IX ECD (rCA IX ECD). The plasmid-
transfected HEK 293T cells were cultured in BelloCell®
Culture System (Chemglass). Production of rCA IX ECD
was done in the EX-CELL 293 serum-free medium
(SAFC Biosciences). Conditioned medium was dialyzed
and rCA IX ECD was purified by FPLC purification on
Ni-precharged HisTrap HP column, concentrated by
dialysis against PBS, and stored at −20 °C. The protein
was diluted 105-times in culture medium (to 10 ng/ml)
immediately before addition to cells.
Immunoblotting
Protein extraction, SDS-PAGE separation, blotting and
immunodetection of CA IX were performed as described
earlier [27].
Enzymed-linked immunosorbent assay (ELISA)
The capture antibody V/10 (10 μg/ml) was immobilized
on the surface of microplate wells overnight at 4 °C.
After blocking and washing, cell extracts or media di-
luted in PBS were added to the coated wells for 2 h at
RT. The attached antigen was then allowed to react with
the mixture of biotinylated MAbs M75 and IV/18 di-
luted 1:7500 (200 ng/ml) in the blocking buffer. The
amount of bound detector antibodies was determined
after 1 h incubation with peroxidase-conjugated strepta-
vidin (Pierce) using the peroxidase substrate orthophe-
nylene diamine (Sigma).
Immunofluorescence
Cells grown on glass coverslips were washed with PBS
and fixed in ice-cold methanol at −20 °C for 5 min. Non-
specific binding was blocked with PBS containing 1 %
BSA for 30 min at 37 °C. Then, the cells were incubated
with the M75 antibody for 1 h at 37 °C followed by anti-
mouse FITC-conjugated horse antibody (Vector Labora-
tories) diluted 1:300 in PBS–BSA for 1 h at 37 °C. The
nuclei were stained with propidium iodide (Sigma). The
coverslips were mounted onto slides in the Fluorescent
Mounting Media (Calbiochem), and the cells were ana-
lyzed with Leica DM4500B microscope and photo-
graphed with Leica DFC480 camera.
Evaluation of apoptosis
Internucleosomal cleavage was visualized by the extraction
of small detergent-soluble fragments of DNA in 0.5 %
Triton X-100, followed by electrophoresis in a 1.5 % agar-
ose gel. Alternatively, apoptotic cells were identified using
the terminal deoxynucleotidyltransferase-mediated dUTP-
biotin nick end labeling (TUNEL) method, as described
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previously [28]. Furthermore, the cells were fixed in ice-
cold methanol, labeled using M75 MAb for 30 min at 4 °C
followed with the FITC-conjugated secondary antibodies
and stained by propidium iodide in the presence of RNAse
A as described below.
Apoptotic cells were quantified by FACS analysis of
the subdiploid DNA content in parallel with the de-
tection of cell surface CA IX. The cells were scraped
from the dishes into culture medium, centrifuged at
low speed, washed twice with PBS, incubated for
30 min at 4 °C with the M75 monoclonal antibody,
centrifuged, washed twice with PBS containing 1 %
FCS and incubated with the secondary anti-mouse
Alexa Fluor 488 antibody for 30 min at 4 °C. Then
the cells were fixed in ice-cold 70 % ethanol for
60 min at −20 °C. Pelleted cells were rehydrated in
PBS, resuspended in 200 μl of RNase A solution
(5 μg/ml RNase A, 0.1 % Tween 20 in PBS) and incu-
bated for 20 min at 37 °C. Eight hundred microliters
of propidium iodide (20 μg/ml stock concentration;
diluted 1:250 in PBS) was added to the cell suspen-
sion and incubated for 5 min at 4 °C. Analysis was
performed on a Becton Dickinson FACScan or Guava
easyCyte 6HT (Millipore) flow cytometers. Data were
analyzed with Cellquest software (Becton Dickinson
Immunocytometry) or with Guava Soft™ software ver-
sion 1.1 (Millipore). Debris, cell doublets and clumps
were excluded from analyses by scatter gating, and a
total of 10,000 single cells were analyzed for each
sample. Cells with less than the 2 N amount of DNA
were classified as apoptotic.
For the comparative viability analysis of the CA IX-
versus CA IX+ cells, the CGL3 cells were first labeled
with M75 and anti-mouse Alexa Fluor 594 antibody,
then incubated with TO-PRO*-3 iodide and sorted
using the FACSAriaTM III sorter (Beckton Dickinson).
TO-PRO*-3-positive dead cells were excluded and the
subpopulations of cells expressing and non-expressing
CA IX (25 % of the highest and lowest M75 staining),
respectively, were plated, allowed to attach for 24 h,
and treated with CHX as described above. The cells
were harvested (at 1 × 106 cells/sample), washed in PBS,
labeled and analyzed by the FACSCanto™ II flow cyt-
ometer (Beckton Dickinson) equipped with the 488 and
633 nm lasers for dye excitation. Labeling of the viable
cells was performed in PBS with 10 nM fluorescein dia-
cetate (FDA) for 25 min at room temperature in the
dark followed by propidium iodide (PI) at a final
concentration of 5 μg/ml. Emitted fluorescence was
collected using the 530/30 filter for FDA and 585/42 fil-
ter for PI. Viable populations showed positive staining
for FDA and negative staining for PI. Data were
analyzed with the FCS Express version 4.0 (De Novo
Software).
Cignal assay
HeLa cells were plated at a density of 40 000 cells per well
(96-well plate). Cignal®TM Cell-based Multi-Pathway Ac-
tivity Assay (SABioscience) was performed according to
instructions of the manufacturer. Recombinant rCA IX
ECD was added for 48 h at final concentration of 10 ng/
ml. Dual-luciferase results were calculated for each trans-
fectant and analyzed by the Data Analysis Software
(SABioscience). Changes in the activity of each signaling
pathway were determined by comparing the normalized
luciferase activities of the reporter in treated versus un-
treated transfected cells.
Statistical analysis
Results were analyzed by two-tailed unpaired t test
(Student’s test), and P < 0.05 was considered significant.
Results
Apoptosis induced by cycloheximide preferentially occurs
in CA IX-negative cells and reduces CA IX expression
Intratumoral CA IX expression has been associated with
poor response to chemotherapy and cancer progression
in several tumor types including carcinoma of the cervix
uteri [29]. To get insight into this phenomenon, we in-
vestigated the relationship between CA IX expression
and the response of cancer cells to cytotoxic treatment.
As a model for the study of CA IX expression during
cell death, we initially decided to use CGL3 cells, which
were generated by fusion of HeLa human cervical car-
cinoma cells with normal human fibroblasts [25]. These
cells represent a tumorigenic segregant of a non-
tumorigenic parental hybrid cell line CGL1. Whereas
CGL1 cells show only very low expression of CA IX in
normoxia and strongly induce CA IX in hypoxia, CGL3
cells express relatively high CA IX levels even under
normoxic conditions. Moreover, flow cytometry revealed
that approximately half of the normoxic CGL3 cells
show the cell surface expression of CA IX and that la-
beling with the CA IX-specific antibody M75 allows for
an easy gating and separate analysis of the CA IX-
positive and CA IX-negative subpopulations growing to-
gether in the same culture dish (see below).
One of the cytotoxic agents that can effectively and
rapidly trigger apoptosis is cycloheximide (CHX), an in-
hibitor of proteosynthesis. In CGL3 cells, CHX was able
to induce all typical biochemical and morphological fea-
tures of apoptosis, as visible from the cell morphology in
the phase-contrast microscope, where the apoptotic cells
appear as dark granular rounded formations compared
to flat translucent living cells (Fig. 1a). Induction of
apoptosis in response to CHX treatment was also
confirmed by the fluorescence analysis of cells using
terminal deoxytranferase-based labeling (Fig. 1b) and by
the DNA electrophoresis (Fig. 1c). Based on the
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appearance of typical apoptotic DNA fragments, we
could clearly see that the onset of apoptosis is rather
fast, proceeding within 2–4 h from the beginning of the
CHX treatment.
We then used flow cytometry to quantitatively correl-
ate the progress of cell death with the cell surface ex-
pression of CA IX in CGL3 cells. For that purpose, we
performed a double labeling of the CHX-treated cells.
The cells were first stained with the M75 antibody
followed by the FITC-conjugated secondary antibody,
then fixed and incubated with propidium iodide to stain
DNA for the detection of subG1 signal corresponding to
fragmented DNA. After data acquisition, we performed
an analysis of the gated CA IX-positive versus CA IX-
negative cells to determine a percentage of the hypodip-
loid cells in each subpopulation. Interestingly, we found
considerably higher percentage of apoptotic cells in the
CA IX-negative cell subpopulation, i.e. 9 ± 2 % after 1 h
treatment with 100 μg/ml CHX, 24 ± 5 % after 2 h treat-
ment and 39 ± 5 % after 3 h treatment compared to the
CA IX-positive cells that showed 4 ± 2 % of apoptotic
cells after 1 h, 5 ± 3 % after 2 h and 7 ± 2 % after 3 h.
Similar difference was observed in CGL3 cells treated
with lower concentration of CHX (20 μg/ml) that
resulted in decelerated progress of apoptosis (Fig. 1d).
These findings suggest that the presence of the cell-
surface CA IX was associated with a decreased sensitiv-
ity to cycloheximide and a prolonged cell survival.
Double immunofluorescence labeling of the CHX-
treated CGL3 cells was in line with the above data, since
the apoptotic nuclei were visible only among the CA IX-
negative CGL3 cells (Fig. 1e).
However, we noticed that the percentage of the CA
IX-positive cells decreased during the progression of cell
death (Fig. 2a). We verified this observation by the im-
munoblotting evaluation of the CA IX levels before and
after the CHX treatment, which clearly showed reduced
amount of the CA IX protein in the lysates from CHX-
treated cells (Fig. 2b). Moreover, we separated dead and
living CGL3 cells by gentle washing out of the dying
cells that do not adhere to support and then scraping off
the adherent living cells. These separated subpopulations
were then analyzed by immunoblotting for the expres-
sion of CA IX. As expected, we found much lower CA
IX level in the dying cells when compared to the living
ones (Fig. 2b). This was confirmed by the ELISA assess-
ment of the cell-associated CA IX in dead versus living
cells (Fig. 2c). Similar results were obtained with the
Fig. 1 Cycloheximide induces apoptosis in CGL3 cells. a Phase-contrast micrograph of the normoxic CGL3 cells treated with 100 μg/ml CHX for 3 h.
Dying cells show typical dark granular appearance. b Fluorescence image of the CHX-treated CGL3 cells subjected to terminal deoxytransferase-based
labeling. The apoptotic cells show nuclear fragments of intense fluorescence. c Electrophoretic analysis of the chromosomal DNA fragmentation in
CGL3 cells treated with 20 μg/ml CHX for 2 h, 4 h, and absence of apoptotic fragments in the control non-treated cells. d FACS analysis of the subG1
cells in subpopulations expressing versus non-expressing CA IX following the treatment with 20 μg/ml CHX for 2 and 4 h and staining with M75 and
propidium iodide. e Staining of the CHX-treated CGL3 cells for CA IX with the M75 MAb and FITC-conjugated secondary antibody (green) and for cell
nuclei with propidium iodide (red). Fragmented apoptotic nuclei are visible in the CA IX-negative cells (see arrows)
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CGL3 cells treated with actinomycin D and dexametha-
sone, respectively (Fig. 2d, e).
CA IX-negative subpopulation of CGL3 cells is more
susceptible to apoptosis
To demonstrate that CA IX expression is linked to bet-
ter cell survival, we labeled the normoxic CGL3 cells
with the CA IX-specific M75 antibody and sorted the
lower 25 % of M75-negative CA IX- subpopulation and
the upper 25 % of M75-positive CA IX+ subpopulation
(Fig. 3a). Then we treated these subpopulations with
CHX and compared their survival based on the sequen-
tial staining with fluorescein di-acetate (FDA), which
emits fluorescence in living cells, followed by propidium
Fig. 2 Progression of apoptosis is associated with reduced CA IX
expression in CGL3 cells. a FACS analysis of the normoxic CGL3 cells
treated with 20 μg/ml CHX and stained for CA IX and DNA content
as described in Fig. 1d. Graph shows the percentage of the subG1
apoptotic cells in the CA IX-negative and the CA IX-positive
subpopulations and changes in the percentage of the CA IX-positive
cells. b Immunoblotting analysis of the CA IX level before (−) and
after the CHX treatment (+) in whole cell population, and in the cells
that died or survived the CHX treatment. c ELISA assessment of the
relative CA IX levels in the CHX-treated CGL3 cells. Error bars
represent the mean ± SD,*p < 0.05. d, e FACS analyses of the CGL3
cells treated with actinomycin D (ActD) and dexamethasone (DX),
stained as in Fig. 1d. The data show reduced proportion of the CA
IX-positive cells in the course of the treatment and faster progression
of apoptosis in the CA IX-negative cells
Fig. 3 CA IX-negative CGL3 cells are more susceptible to apoptosis. a
Representative FACS analysis of the CA IX expression in the sorted CA IX-
negative (CA IX-) versus CA IX-positive (CA IX+) CGL3 cell subpopulations,
and relative CA IX expression in the sorted subpopulations from four
independent experiments. b Representative FACS analysis of the cell
viability in the sorted subpopulations using double staining with the
fluorescein di-acetate and propidium iodide. c Proportion of the viable,
apoptotic and necrotic cells in the sorted subpopulations under control
conditions and after treatment with CHX, as determined by FACS of
FDA-PI staining in four independent experiments. CHX-treated CA IX cells
showed significantly higher viability than CA IX- cells. Error bars represent
the mean ± SD. **p< 0.01
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iodide, which accumulates in late apoptotic and necrotic
cells depending on the degree of their membrane disrup-
tion. Indeed, we found a significantly lower proportion
of viable cells and a higher proportion of both apoptotic
and necrotic cells in the CA IX- subpopulation than in
the CA IX+ counterpart (Fig. 3b, c), supporting the view
that the expression of CA IX is associated with reduced
vulnerability to cell death.
Loss of CA IX in dying cells is sensitive to
metalloproteinase inhibition
In accord with the known phenomenon of global proteo-
lytic release of cell surface proteins associated with apop-
tosis [30], we decided to examine the possibility that the
CA IX ECD is increasingly cleaved from the dying cells.
Level of the shed CA IX ECD was assessed using sandwich
ELISA with the CA IX-specific monoclonal antibodies
binding to the N-terminal PG-like domain and the catalytic
CA domain [9]. We found that the CHX-treated cells pro-
duced significantly higher CA IX ECD levels when com-
pared to non-treated cells (Fig. 4a). Similar increase was
observed under both normoxia and hypoxia, although the
total extracellular level of CA IX ECD was higher in hyp-
oxic cells independently of the CHX treatment.
We previously showed that the CA IX shedding is a
metalloproteinase-dependent process, which can be re-
duced by the metalloproteinase inhibitor batimastat, i.e.
BB-94 [9]. In agreement with this earlier finding, pre-
treatment of the cells with BB-94 led to a decreased level
of the CA IX ECD in the culture medium of the CHX-
treated cells supporting the idea that induction of apop-
tosis led to the activation of metalloproteinases involved
in the shedding of the CA IX ECD (Fig. 4a). Noteworthy,
BB-94 itself had no significant effect on the extent of cell
death (Fig. 4b).
In addition, we evaluated the viability of ADAM17-
competent CHO-wt versus ADAM17-defective CHO-
M2 cells transiently expressing CA IX and treated with
PMA (since these cells are not sensitive to CHX). We
found that the ADAM17-competent cells, which shed
CA IX, displayed reduced viability in response to PMA
when compared to the ADAM17-defective cells, which
are unable to cleave the CA IX ectodomain to culture
medium (Fig. 4c,d).
Doxorubicin induces CA IX ECD shedding
Next we wanted to test whether clinically used chemo-
therapeutic drugs represented here by doxorubicin could
Fig. 4 Inhibition of metalloproteinases reduces shedding, but does not block apoptosis. a ELISA detection of the CA IX ECD in the culture media
of CHX-treated versus non-treated CGL3 cells in the presence or absence of the metalloproteinase inhibitor BB-94. BB-94 significantly reduces
shedding of the CA IX ECD. b FACS analysis of the proportion of dead cells (based on PI uptake) in the corresponding populations of the CHX-
and/or BB-94-treated cells compared to non-treated controls. BB-94 showed no significant effect on cell death. c FACS analysis of the viability of
the ADAM17-competent CHO-wt cells (wt) versus ADAM17-defective CHO-M2 cells (ADAM17-) treated or not by PMA. Slower progression of cell
death can be seen in ADAM17- cells. d ELISA detection of the shed CA IX ECD from the same CHO cell cultures. Data confirm that CA IX ECD
shedding is ADAM17-dependent. Error bars represent the mean ± SD. **p < 0.01, *p < 0.05
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also trigger the CA IX ECD shedding from the dying
cancer cells. In addition to CGL3 cells, we also included
HeLa cells as well as MDCK-CA9 transfectants, which
express CA IX protein independently of hypoxia and
other pathways regulating the transcription of the CA9
gene, and thus allow for reliable evaluation of the effi-
cacy of the shedding itself. The cells were incubated for
24 h in normoxia and hypoxia, respectively, in the ab-
sence or presence of 1 μg/ml doxorubicin (DOX), col-
lected and stained first with the M75 antibody to detect
the cell surface CA IX, then fixed and incubated with
propidium iodide to stain DNA. The cells were analyzed
by flow cytometry to determine % of CA IX-positive
cells and % of subG1 cells undergoing apoptosis. Simul-
taneously, we collected the culture media of the analyzed
cells and used it for the determination of the shed CA
IX ECD level.
Consistent with the data obtained above with CHX,
we could observe that the increased apoptotic death in
DOX-treated cells was associated with the decreased
cell-surface expression of CA IX (Fig. 5a, b). This was
accompanied by increased CA IX shedding and elevated
ECD in the culture medium (Fig. 5d). Moreover, apoptosis
was preferentially triggered in the CA IX-negative subpop-
ulation supporting the view that cells eliminate CA IX
though shedding of its ECD at the onset or early during
cell death (Fig. 5c). Since the experiment was performed
in normoxia, HeLa cells showed only a weak CA IX ex-
pression and low percentage of the CA IX-positive cells
in the population. On the other hand both CGL3 cells and
MDCK-CA9 cells displayed relatively high CA IX
expression.
When exposed to hypoxia, all cell lines, including
HeLa, expressed CA IX levels in an increased percentage
of cells in culture when compared to normoxic cells
(Fig. 6). Again, apoptosis was confined to the CA IX-
negative subpopulation of cells and was accompanied by
more dramatic loss of cell surface CA IX and higher
ECD shedding.
We also wanted to see, whether inhibition of the exec-
utors of apoptosis can affect the CA IX ECD shedding.
Therefore, we treated HeLa cells with the pan-caspase
inhibitor Z-VAD-FMK. Since CA IX expression in HeLa
cells depends on hypoxia, we first incubated the cells in
hypoxia for 24 h, then added the inhibitor followed by
DOX 6 h later. The culture medium was harvested after
Fig. 5 Doxorubicin-induced apoptosis is associated with reduced CA IX expression and increased CA IX ECD shedding in normoxic cells. a FACS
analysis of the subG1 fraction in the control and DOX-treated cells determined by the DNA labeling with propidium idodide, b and corresponding
proportions of the M75-labeled CA IX-positive cells in the same cell samples. c Percentage of the CA IX- and CA IX+ cells within the DOX-treated dead
cells. Data show that the dying cells are principally CA IX-negative. d Increased levels of the CA IX ECD shed from the DOX-treated versus control
normoxic cells. Grey lines illustrate the DOX-related fold induction of the CA IX ECD shedding. Error bars represent the mean ± SD. **p < 0.01, *p < 0.05
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20 h and analyzed for the CA IX ECD (Fig. 7a). As ex-
pected, the pan-caspase inhibitor Z-VAD-FMK de-
creased the level of the CA IX ECD in the DOX-treated
cells, suggesting that the execution of apoptosis contrib-
utes to the induction of CA IX cleavage. Interestingly,
the DOX-increased shedding was associated with the
significantly elevated CA IX transcription in the cells
surviving the treatment, but this elevation was partially
blunted by the pan-caspase inhibitor Z-VAD-FMK, sug-
gesting a feedback regulation by which shedding-related
CA IX loss from the cell surface may be compensated by
its de novo synthesis (Fig. 7b).
CA IX ECD contributes to intracellular signaling
The above-described transcriptional changes in the ex-
pression of CA IX prompted us to investigate potential
signaling effects of the externally added CA IX ECD. To
this end we performed the CIGNAL analysis of the nor-
moxic HeLa cells in the presence versus absence of the
recombinant CA IX ECD (rCA IX ECD). Since under
normoxia, HeLa cells show no or only very weak expres-
sion of endogenous CA IX, they release no or low CA
IX ECD and are thus suitable for such analysis. Exposure
of HeLa cells to rCA IX ECD at 10 ng/ml concentration
(that is achievable in human sera [18]) led to the activa-
tion of the pathway executed by the Nanog transcription
factor implicated in epithelial-mesenchymal phenotype
and stemness [31]. On the other hand, pathways driven
by the transcription factors mediating stress responses
or tumor suppression, including GATA, SMAD2/3/4
and MEF2 were dowregulated [32–34], (Fig. 7c). Interest-
ingly, qPCR analysis demonstrated significantly increased
transcriptional levels of Nanog in the ECD-treated HeLa
cells, supporting the CIGNAL data (Fig. 7d). These
findings indicate that the CA IX ECD can participate in
autocrine/paracrine signaling to cancer cells and con-
tribute to transcription of genes implicated in tumor
phenotype. Nevertheless, tumor milieu contains many
other soluble factors that may accentuate or attenuate
the CA IX ECD signaling.
Discussion
Ectodomain shedding is an important molecular mech-
anism regulating cell surface density and/or activity of a
number of transmembrane proteins implicated in signal
transduction, such as receptors (EGFR, TNRF, IL-6R,
Fig. 6 Doxorubicin-induced apoptosis and CA IX ECD shedding in hypoxic cells. a FACS analysis of the subG1 fraction in the control and DOX-
treated cells exposed to hypoxia (2 % oxygen), (b) and corresponding proportions of the M75-labeled CA IX-positive cells in the same cell samples.
c Percentage of the CA IX- and CA IX+ cells within the DOX-treated dead cells. d Absolute levels and fold induction of the CA IX ECD shed from the
DOX-treated and control hypoxic cells. Hypoxia induces CA IX expression and boosters the effects of DOX on apoptosis and shedding. Error bars
represent the mean ± SD. **p < 0.01, *p < 0.05
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Notch), adhesion molecules (CD44, VCAM, cadherins),
growth factors and cytokines (HB-EGF, TGFα, TNFα, IL-
6) [35]. It occurs constitutively at low basal levels, but
can be strongly induced in response to diverse stimuli
including cytotoxic stress associated with anticancer
therapy. Chemotherapy-induced apoptosis elevates tran-
scription and activates ADAM17, a principal metallopro-
teinase that orchestrates shedding and pro-survival
responses in cancer cells through the release of factors
that enhance tumor growth via autocrine and/or para-
crine signaling [36–38].
Here we showed that CA IX, a hypoxia-induced protein
expressed on the surface of tumor cells exhibits increased
ectodomain shedding from cells undergoing apoptosis in-
duced by cytotoxic compounds. This phenomenon can be
observed as an acute response to the inhibitor of macro-
molecular synthesis cycloheximide, as well as a response
to the chemotherapeutic drug doxorubicin. Similar effects
on CA IX ECD shedding were obtained with actinomycin
D and dexamethasone. This apoptosis-associated shedding
can be inhibited with a broad metalloproteinase inhibitor
batimastat in agreement with the fact that CA IX is an
ADAM17 substrate [9]. In contrast, BB-94 cannot block
the onset of apoptosis indicating that shedding is not the
prerequisite, but rather a consequence of apoptosis. This
is in line with other recently published studies [37, 38]
and also with our observation that the pan-caspase inhibi-
tor Z-VAD-FMK can reduce the CA IX ECD shedding.
These data may indicate that the elevated CA IX ECD
in the blood of tumor patients can result from efficient
chemotherapy leading to cell death and tumor shrinkage.
Moreover, taking into account the role of the plasma
membrane CA IX in the protection of tumor cells from
hypoxia and acidosis and in migration-invasion, we
might speculate that reducing the surface density of CA
IX through its ECD shedding could make tumor cells
less invasive and more vulnerable to microenviron-
mental stresses. Albeit so far there is only one study
supporting the role of ECD (actually, of an increased
post-treatment ECD level) as an indicator of a good
outcome of neoadjuvant chemotherapy [39], there are
dozens of clinical papers showing that the high cell-
surface expression of CA IX is linked to chemoresis-
tance and a more aggressive tumor phenotype [14].
However, the situation is not so simple (1) because ele-
vated shedding in dying subpopulation of cells leads to
an increased CA IX expression in the surviving subpop-
ulation of cells and (2) because ECD itself can induce
transcription of genes implicated in stem-like, pro-
metastatic phenotype through Nanog mRNA elevation
and transactivation of the Nanog-driven pathways.
Translating these findings into tumor biology would sug-
gest that the cytotoxic treatment might preferentially kill
subpopulation of cells, which do not express CA IX or
which lose CA IX through elevated ECD shedding, and
spare those cells that retain CA IX on their surface. At
the same time, ECD released from the dying cells might
signal to surviving cells and affect their phenotype
through modulation of their transcriptional program.
This would then create the basis for the outgrowth and
progression of resistant tumor cells. Further translating
these assumptions into clinical context, this would mean
that high blood level of the CA IX ECD might be an un-
wanted negative effect of chemotherapy that promotes
tumor progression through the CA IX ECD-emitted sig-
naling. Mechanism(s) behind this signaling remain to be
elucidated, but it is quite conceivable that the ECD binds
to a so far unknown receptor and thereby mediates sig-
nal transduction to intracellular pathways, such as the
one driven by Nanog. Interestingly, MatInspector-based in
silico analysis of the CA9 promoter showed that it con-
tains a putative binding site for the Nanog transcription
Fig. 7 Pan-caspase inhibitor Z-VAD-FMK (Z-VAD) reduces CA IX
shedding and expression in hypoxic HeLa cells, and recombinant CA
IX ECD induces the Nanog pathway. a ELISA of the CA IX ECD shed
from the whole population of the DOX and Z-VAD-FMK-treated cells.
b qPCR analysis of the CA IX transcript level in the viable fraction of
cells. DOX-surviving cells show higher ECD shedding and higher
transcription of CA IX, whereas Z-VAD inhibits the ECD release and
reduces CA IX transcription. c Cell-based dual luciferase reporter
assay of HeLa cells incubated in the presence of recombinant rCA IX
ECD showed alterations of several signal transduction pathways
leading to changes in transactivation activities of the transcription
factors indicated in the graph. d qPCR analysis confirmed the induction
of Nanog gene transcription in the rCA IX ECD-treated cells. Error bars
represent the mean ± SD. **p < 0.01, *p < 0.05
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factor (-89/-107 position, matrix similarity 0.959) thus of-
fering an explanation for the feedback regulation of the
CA9 transcription via CA IX ECD [40].
This scenario is compatible with several reports linking
high CA IX expression in tumors and/or high CA IX ECD
levels with resistance to chemotherapy (including doxorubi-
cin), increased survival of tumor cells, stem-like phenotype
and poor prognosis of tumor patients [15–19, 41–44]. It is
also supported by experimental studies showing that the
CA IX expressing cells are viable, clonogenic and resistant
to killing by ionizing radiation [45, 46], in line with our
findings of the reduced cell death in the CA IX-positive
cells and increased CA IX expression in the cells surviving
the cytotoxic treatment. Moreover, CA IX expression has
been implicated in activation of stromal fibroblasts and
their crosstalk with prostate cancer cells resulting in the in-
creased cancer invasiveness [47]. Although the authors do
not consider a role for CA IX shedding, it cannot be
excluded that the observed pro-metastatic effects are
at least partially mediated by the paracrine signaling
of the CA IX ECD. Last but not least, induction of
EMT-related pathways/genes (such as Nanog) ob-
served here is in line with earlier data showing that
CA IX ECD can inhibit cell adhesion [48] and sug-
gests that it may contribute to detachment and dis-
semination of cancer cells.
Taking into account these controversial outcomes of
the CA IX ECD shedding, it is also well conceivable
that in the reports that failed to find any significant
relationship of the CA IX ECD levels to clinico-
pathological correlates [20–22], we actually face a com-
plex situation, in which some patients may release CA
IX ECD as a consequence of a complete response to
therapy, whereas others may release CA IX ECD as a
partial response to therapy that later resumes in recur-
rence. This latter subgroup of patients could be poten-
tially identified by detection of CA IX in metastases.
Albeit data from such studies are rare, there are few
reports showing that CA IX is indeed expressed in
metastatic lesions [49–52].
Taking together, here we reveal the CA IX ECD shed-
ding as a response to cell death induced by cytotoxic
drugs and propose how it might affect tumor biology
and influence the interpretation of clinical data from the
assessment of the soluble CA IX levels in cancer pa-
tients. Nevertheless, this study provides only initial
insight into the potential role of CA IX ECD in cancer
development, and additional thorough investigations are
needed to better understand this phenomenon.
Conclusions
Intratumoral expression of the hypoxia biomarker CA
IX has been associated with poor response to chemo-
therapy in many independent studies. Here we showed
that: (1) CA IX expression offers survival advantage in
cancer cells treated with cytotoxic drugs, (2) induction
of apoptosis triggers an increased CA IX ectodomain
shedding, (3) CA IX ectodomain contributes to para-
crine signaling. These findings support the role of the
circulating CA IX ectodomain as an indicator of
chemotherapy response and as a signaling molecule im-
plicated in cancer progression.
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